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Background: ATG has been employed to deplete T cells in several immune-mediated conditions. However,
whether ATG administration affects naïve and memory T cell differently is largely unknown.
The context and purpose of the study: In this study, we assessed how murine ATG therapy affected T cell
subsets in NOD mice, based on their regulatory and naïve or memory phenotype, as well as its influence on
antigen-specific immune responses.
Results: Peripheral blood CD4+ and CD8+ T cells post-ATG therapy declined to their lowest levels at day 3, while
CD4+ T cells returned to normal levels more rapidly than CD8+ T cells. ATG therapy failed to eliminate
antigen-primed T cells. CD4+ T cell responses post-ATG therapy skewed to T helper type 2 (Th2) and possibly
IL-10-producing T regulatory type 1 (Tr1) cells. Intriguingly, Foxp3+ regulatory T cells (Tregs) were less sensitive to
ATG depletion and remained at higher levels following in vivo recovery compared to controls. Of note, the
frequency of Foxp3+ Tregs with memory T cell phenotype was significantly increased in ATG-treated animals.
Conclusion: ATG therapy may modulate antigen-specific immune responses through inducing memory-like
regulatory T cells as well as other protective T cells such as Th2 and IL-10-producing Tr1 cells.
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Anti-thymocyte globulin (ATG), trade name thymoglo-
bulinW, has been employed for decades as an immune
modulator for a variety of clinical indications. It is cur-
rently one of the most common immunosuppressive
reagents used in allogeneic transplantation [1-3] and
more recently, in the treatment of a variety of auto-
immune disorders [4-8]. There is a common belief that
ATG therapy functions through complement mediated
depletion of mature T cells. However, recent data* Correspondence: cqx65@yahoo.com
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reproduction in any medium, provided the orsuggests that ATG therapy induces immune modulation
beyond that of simple T cell depletion [9]. For example,
ATG therapy may facilitate tolerance induction through
modulation of dendritic cells (DC), both phenotypically
and functionally [10]. Evidence has also shown that ATG
therapy may also induce regulatory T cells (Tregs)
in vivo [11-13]. However, it remains unclear how ATG
therapy affects naive and memory T cells in autoimmune
settings such as T1D, although a recent study suggested
that ATG therapy effectively eliminates alloantigen spe-
cific memory T cells in an allogeneic transplantation
mouse model [13]. In the current study, we used both
standard NOD mice, as well as a TCR transgenic form
of these mice (i.e., NOD.BDC2.5) to investigate changes
within immune cell subsets in peripheral blood, spleen. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on addressing the questions of how ATG therapy
affected naive and memory T cells, including naïve and
memory Tregs. These strains were utilized due to their
common utilization in studies of murine ATG efficacy
for type 1 diabetes, as well as the ability to utilize mice
having a defined antigenic specificity. The results de-
monstrated that ATG therapy differentially depletes
T cells from peripheral blood and lymphoid organs. ATG
therapy was more efficient in depleting naïve T cells than
memory T cells. Tregs appeared resistant to ATG deple-
tion and their frequency remained at increased levels after
homeostatic recovery from ATG therapy. It was also noted
that proportionately Tregs with memory T cell phenotype
were significantly increased post-ATG therapy. Taken col-
lectively, we believe this is a previously unrecognized
mechanism whereby ATG therapy differentially affects
naïve and memory Tregs.
Methods
Mice
Female NOD/Ltj were purchased from Jackson Labora-
tory and housed in specific pathogen free facilities at
University of Florida Animal Care Service. The Institu-
tional Animal Care and Use Committee at University of
Florida approved all animal procedures (approval ID:
20090279).
Media and reagents
RPMI1640 media with glutamine were purchased from
Fisher Scientific (Pittsburgh, PA). Complete culture
media were prepared using RPMI1640 plus 10% fetal bo-
vine serum (Thermo Scientific, Waltham, MA) and 1x
penicillin and streptomycin (Cellgro, Manassas, VA).
Murine ATG was provided by Genzyme (Framingham,
MA). Rabbit IgG isotype was purchased from the
Jackson Laboratory. The following antibodies were pur-
chased from BD Biosciences: (San Jose, CA): CD4-PerCp
(clone RM4-5), CD8-FITC (clone 53–6.7), B220-APC
(clone RA3-6B2), CD44-APC (clone IM7), CD11c-APC
(clone HL3), CD3-PE (clone 17A2) and CD25-APC
(clone PC61). The antibodies of CD62L-APC and –FITC
(mEL-14) and CD11b-PE (m1/70) were purchased from
eBioscience (San Diego, CA). Gr1 (Ly6G/Ly6C)-APC
(clone RB6-8C5) and Foxp3-PE, -FITC (clone MF-14)
were purchased from BioLegend (San Diego, CA). Cell-
Trace CFSE kits, and CD3, CD28 antibody-coated Dyna-
beads were purchased from Invitrogen (Carlsbad, CA).
Multiplex bead cytokine assay kits were purchased from
Millipore (Billerica, MA). Mouse CD11c beads were pur-
chased from Miltenyi Biotech (Germany). CD4+ T cell
negative selection kits were purchased from StemCell
Biotechnology Inc. (Vancouver, Canada). KLH was pur-
chased from CalbioChem (San Diego, CA). Bovineserum albumin was purchased from Sigma-Aldrich
(St. Louis, MO). Alum adjuvant was purchased from
Thermo Scientific (Waltham, MA).
ATG treatment and observation of peripheral blood cell
components
6–8 week old NOD mice were treated with two intraperi-
toneal injections of ATG or isotype IgG (500 ug/mouse), 3
days apart, as previously described [11,12]. In some
experiments, two groups of mice were monitored longitu-
dinally by examining white blood cell lineages using flow
cytometry (LSRFortessa, BD) including CD4+, CD8+
T cells, B220+ B cells, Gr-1+ granulocytes as well as
CD62L+ naive T cells and CD62-CD44+ memory T cells.
The data were analyzed by FCS express De Novo software
version 3 (Vancouver, Canada).
Measurement of splenic memory and naive T cells and T
cell response to in vitro stimulation post ATG therapy
NOD mice were treated with ATG and isotype IgG as
described above. At day 3 or 22, the treated mice were
sacrificed. Single cell suspensions of spleen cells were
prepared and CD4+, CD8+ T cells as well as CD62L+
naive and CD62-CD44+ memory T cells were examined
by flow cytometry (LSRFortessa, BD). A portion of the
spleen cells were used for CD4+ T cell isolation using
CD4+ T cell negative isolation EasySep kits following the
manufacturer’s instructions (StemCell Inc. Canada).
Spleen cells (1 × 106) were stimulated with anti-CD3
antibody (3 ug/ml) and in some experiments, purified
CD4+ T cells were stimulated with CD3 and CD28
antibody-coated Dynabeads mouse T cell activator (Invi-
trogen), with splenic DC plus antigens (KLH), or autoan-
tigens (NIT-1 cell lysates) as indicated for 3–4 days,
then, 3H-thymidine (1 uCi/well) was added to each well
for the final 16 hours. Incorporation of 3H-thymidine
was measured by scintillation counting (Wallac Trilux).
Measurement of Foxp3+ Treg cells
Spleen cells were stained with anti-CD4-PerCp and anti-
CD25-APC. The cells were then fixed and permeablized
and stained with anti-Foxp3-PE following the instructions
of the manufacturer (eBioscience). CD4+CD25+Foxp3+
Treg cells were examined by flow cytometry (LSRFortessa,
BD) and analyzed by FCS express De Novo Software ver-
sion 3.
Splenic CD4+ T cell and CD11c+ DC isolation
Spleen cells were freshly prepared. Purified CD4+ T cells
were prepared using EasySep CD4+ T cell negative sec-
tion kit (StemCell Technologies Inc, Vancouver, Canada),
and splenic DCs were labeled with anti-CD11c-microbe-
ads, and then isolated by magnetic cell sorting following
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CD4+ T cells and CD11c+ DC was approximately 95%.
KLH immunization and recall response assay
NOD mice were treated with ATG or isotype IgG as
described above along with simultaneous immunization
by intraperitoneal injections of KLH (25 ug/mouse) in
adjuvant Alum. The treated mice were sacrificed at day
22 post-ATG therapy and harvested cells were cultured
with stimulators as indicated, or medium only for 4 days.
Supernatants (50 ul/well) were harvested and stored for
later cytokine assay. Then, 3H-thymidine (1 uCi/well)
was added to the cultures and incubated for additional
16 hours. 3H-thymidine incorporation was measured as
described above.
Autoantigen immunization and recall response in vitro
and in vivo
NIT1 cells (NOD insulinoma cell line) were cultured
according to the method provided from the vendor
(ATCC). NIT1 cells (2 × 107) were suspended into 1 ml
PBS. The cell suspension underwent freeze-thaw proce-
dures 4 times to prepare NIT1 cell lysates. NOD mice
(6 weeks old) were treated with ATG or isotype IgG as
described above along with intraperitoneal injections of
50 μl of NIT1 lysates in 50 μl of Alum.
In vitro antigen recall response assay
A week following the last treatment, all mice were
sacrificed and spleen cells prepared and stimulated
with NIT1 lysates (10 ul/well), a control antigen KLH
(10 ug/ml), or medium for 4 days. Supernatants (50 ul/
well) were harvested and stored for later cytokine assay.
Then, 3H-thymidine (1 uCi/well) was added to the cul-
tures and incubated for additional 16 hours. 3H-thymidine
incorporation was measured by scintillation counting. A
portion of the spleen cells from the above mice were
used for CD4+ T cell isolation. The isolated CD4+ T cells
(2 × 105/well) were stimulated with splenic dendritic cells
(2 × 104/well) purified from naive NOD mice in the pres-
ence of NIT1 lysates (20 μl/well). The T cell proliferation
was measured by 3H-thymidine incorporation assay, as
described above.
In vivo antigen recall response assay
In these experiments, we stained a portion of spleen
cells prepared above with carboxyfluorescein succinimi-
dyl ester (CFSE) following the instructions from the
manufacturer (Invitrogen). Then, we adoptively trans-
ferred CFSE-labeled spleen cells (2 × 107/mouse), as pre-
pared above, into 8-week-old NOD mice. Four days
later, the mice were sacrificed and pancreatic lymph
node cells, as well as cells from inguinal lymph node,
were prepared and the CFSE-labeled T cell proliferation(dilution of CFSE) was examined by flow cytometry. In
these experiments, we chose to use CFSE-labeled whole
spleen cells but not purified CD4+ T cells because the
whole spleen cells would be more reflecting the T cell
behaviors post-ATG therapy.
Cytokine assay
Cytokine concentrations in culture supernatants, includ-
ing IFN-γ, IL-4, IL-5 and IL-10, were measured by multi-
plex cytokine assay kits using Luminex 100 (Luminex
Map Technology) following the instruction from the
manufacturer (Millipore).
Statistical analysis
Data were analyzed using Student t testing. Differences
with p<0.05 were considered to be statistically significant.
Results
ATG therapy efficiently depletes T cells from peripheral
blood, but is less efficient in depleting T cells from
lymphoid organs
It is known that ATG therapy can largely eliminate T
cells from peripheral blood. However, it was of interest
to learn to what extent ATG eliminated T cells from
lymphoid organs. Our kinetic observation of peripheral
blood cells post-ATG therapy revealed that both the
CD4+ and CD8+ T cells dropped to their lowest levels at
day 3 post-ATG therapy and by day 22, peripheral blood
CD4+ T cells returned to normal levels. In contrast,
whereas CD8+ T cells were shown to recover, they
remained significantly lower than at baseline by day 22
(Figure 1A and Additional file 1: Figure S1). Based on
the kinetic changes of blood T cells above, in subsequent
experiments, we compared CD4+ and CD8+ T cells in
peripheral blood and spleen at day 3 and day 22 post-
ATG therapy. Again, we found that at day 3 post-ATG
therapy, both CD4+ and CD8+ T cells were drastically
reduced in peripheral blood (Figure 1B and D). In con-
trast, the reduction of both T cell populations in spleen
at day 3 post-ATG therapy was significantly less than in
peripheral blood (Figure 1C and D). We did not find sig-
nificant differences between ATG and isotype IgG trea-
ted animals in terms of the spleen size and the total cell
numbers in spleen at day 3 post-ATG therapy (data not
shown and Additional file 1: Figure S2). Therefore, the
percentage change would reflect the absolute number
change in splenic T cells. Again, by day 22 post-treat-
ment, the percentage of CD4+ T cells did not show sig-
nificant differences between the ATG group and isotype
IgG group, in both blood and spleen (Figures 1B, C and
Additional file 1: Figure S1). However, CD8+ T cells
were significantly lower in the ATG group than in con-
trol animals, in both blood and spleen (Figure 1B, C and
Additional file 1: Figure S1). These results indicate that
Figure 1 ATG therapy differentially depletes T cells from peripheral blood and lymphoid organs. NOD mice were treated with ATG or
isotype IgG twice with a 3-day interval. Then, CD4+ and CD8+T cells in peripheral blood were examined by flow cytometry every 3 days until day
22. A shows CD4+ and CD8+ T cell percentages in total peripheral white blood cells at different time points post ATG therapy (n=4 mice in each
group); B and C show CD4+ and CD8+ T cell percentages in peripheral white blood cells and spleen cells, respectively (n=3 mice in each group).
D exhibits CD4+ and CD8+ T cell depletion rates in peripheral blood and spleen at day 3 post ATG therapy, respectively (n=3 mice in each
group). The similar results were obtained in additional two independent experiments.
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blood and that CD4+ T cells recover faster than CD8+ T
cells.
ATG therapy differentially depletes naive and memory
T cells from the peripheral blood and spleen
It is still a matter of debate whether ATG therapy prefer-
entially depletes certain subsets of T cells [4,14-17]. In
these experiments, we investigated changes of naive and
memory T cells using CD62L and CD44 markers (shown
in Figure 2), respectively, in peripheral blood and spleen,
at day 3 and day 22 post-ATG treatment. We discoveredBlood
A
Figure 2 ATG therapy differentially depletes naive and memory T cel
or isotype IgG twice with a 3-day interval. At day 3 post treatment, CD62L+
were examined by flow cytometry and analyzed by gating CD4+ T cells as
summary of the percentages of CD62L+CD4+ T and CD44+CD62L- CD4+ T
panels). B shows the summary of the percentages of above T cell subsets i
mice were included in each group. Three independent experiments were pthat CD62L+CD4+ (Figures 2A and B) and CD62L+CD8+
naive T cells (data not shown) were significantly reduced
at day 3 post-ATG therapy, in contrast to the Isotype IgG
group, in both peripheral blood and spleen. Of interest,
the percentage of CD62L-CD44+ CD4+ T cells (Figure 2A
and B) and CD62L-CD44+CD8+ T cells (data not shown)
in total CD4+ and CD8+ T cells, respectively, were signifi-
cantly increased in the ATG group compared to the con-
trol group. These results suggest that ATG therapy may
preferentially deplete naive T cells. However, by day
22 post-treatment, there were no differences between
two groups in the frequency of naive and memory CD4+Spleen
B
ls in peripheral blood and spleen. NOD mice were treated with ATG
CD4+ and CD44+CD62L-CD4+ T cells in peripheral blood and spleen
depicted in the upper panels of A and B, respectively. A shows the
cells in total CD4+ T cells in the peripheral blood, respectively (lower
n total CD4+ T cells in spleen cells, respectively (lower panels). Three
erformed with similar results.
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differences between isotype IgG treated and non-treated
NOD mice (data not shown).
ATG therapy does not affect the response of the
remaining non-depleted T cells to TCR stimulation, but
induces decreased levels of Th1 and enhanced levels of
IL-10-producing T cells
To determine whether the immune response of T cells
that are not depleted by ATG therapy alters, at day 3
post-treatment, we prepared spleen cells from ATG or
isotype IgG treated NOD mice and stimulated them with
anti-CD3 antibodies. T cell proliferation was measured
by 3H-thymidine incorporation assay. We found that theFigure 3 Proliferation of T cells from mice treated with ATG or isotyp
treated with ATG or isotype IgG twice with a 3-day interval. A, At day 3 po
antibodies for 3 days, then 3H-thymidine (1 uCi/well) was added to the cul
measured by scintillation counting. Three mice were tested in each group.
purified CD4+ T cells were stimulated with anti-CD3 and anti-CD28 antibod
added to the cultures for additional 16 hours. T cell proliferation was exam
in the cultures from 3 animals in each group in B was measured by Lumin
(993.3±141.0 v.s. 366.7±96.1) and (1117.0±202.8 v.s. 3793±795.5), respective
Student t test is significant with p value as of 0.0221 and 0.0253, respective
similar results.proliferation of T cells from spleen cells of ATG-treated
animals was significantly lower than those obtained from
isotype IgG treated animals (Figure 3A). The reduced T
cell proliferation was likely attributable to the lower fre-
quency of T cells in spleen cells from ATG-treated mice.
To address whether ATG treatment directly modulates
T cells and alters their response to TCR activation, we
purified CD4+ T cells (purity >95%) and stimulated them
with CD3 and CD28 antibody coated Dynabeads. Then,
T cell proliferation was examined by 3H-thymidine in-
corporation assay. We did not observe significant dif-
ferences in terms of T cell proliferation between the
two groups (Figure 3B). Characterization of cytokine-
producing profiles of CD4+ T cells demonstrated thate IgG in response to CD3 antibody stimulation. NOD mice were
st treatment, spleen cells were prepared and stimulated with anti-CD3
tures for additional 16 hours. 3H-thymidine incorporation was
B, part of the above spleen cells was used to isolate CD4+ T cells. The
y coated beads for 3 days. Thereafter, 3H-thymidine (1 uCi/well) was
ined by the method described above. C, the production of IL-10, IFN-γ
ex. The values for IL-10 and IFN-γ for treatment group and controls are
ly. The difference between the two groups for IL-10 and IFN-γ by
ly. An additional independent experiment was performed with the
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cantly higher levels of IL-10 with reduced levels of
IFN-γ, in contrast to those from isotype IgG treated
mice (Figure 3C). These data indicate that ATG ther-
apy skew T cell responses to IL-10-producing T cells
including Th2 and Tr1.
CD4+Foxp3+ Tregs are less sensitive to ATG depletion
and remain at an increased frequency post CD4+ T cell
recovery
To determine whether Tregs undergo depletion post-
ATG therapy, NOD mice at 6 weeks of age were treated
with ATG or isotype IgG as described earlier. We then
sacrificed one-half of the mice (n=3) from each group
at day 3, and the rest (n=3) at day 22 post-treatment,
respectively, and examined the proportion of Foxp3+
CD4+ T cells of total CD4+ T cells as well as their abso-
lute numbers. As shown in Figure 4A and B, compared
to the isotype IgG group, the ATG group demonstrated
a significantly increased percentage of CD25+Foxp3+
CD4+ T cells in total CD4+ T cells at day 3 post-therapy
and comparable levels of absolute numbers of these
cells, suggesting that Foxp3+ Tregs were resistant to
ATG mediated depletion. Moreover, at day 22, when
CD4+ T cells were recovered, Tregs remained at higher
levels in the ATG treated group than in the isotype IgG
group (Figure 4C and D). Of interest, the proportionate
increase of the Tregs out of total CD4+ T cells in lymph
nodes was even more dramatic in the ATG compared to
the isotype IgG group at day 3 post-treatment (Figure 4E
and G). The same trend was also observed for Treg’s ab-
solute numbers (Figure 4F and H).
ATG therapy drives more CD62L- memory type Tregs
We demonstrated (Figure 2) that ATG preferentially
depletes CD62L+ naïve T cells. It was then of interest to
learn whether ATG therapy depleted naïve and memory
Tregs differently. In these experiments, we examined
splenic Tregs at day 3 post-ATG or isotype IgG treat-
ment using flow cytometry. We gated CD4+CD25+ T
cells and then analyzed for the expression of Foxp3 and
CD62L. Surprisingly, we noted that ATG therapy signifi-
cantly reduced CD62L+ naïve Tregs compared to isotype
IgG treated animals (Figure 5A and B). This finding sug-
gests that the preservation of CD62L- memory Tregs
may play an important role for ATG to modulate
antigen-specific immune responses.
ATG therapy fails to eliminate antigen primed T cell, but
skews antigen-specific immune responses to Th2 and/or
Tr1 cells
As noted earlier, ATG has been used for a variety of
immune-mediated conditions such as allogeneic trans-
plantation and autoimmune diseases. One hope for ATGtherapy would be its ability to eliminate most antigen-
specific T cells so that immune responses against allo-
graft or self-tissues could be avoided. For example, in
settings of autoimmune diabetes, a majority of β cell
antigen-specific T cells are presumably primed and be-
come β antigen-specific effector or memory T cells. In
allogeneic transplantation, alloantigen-specific T cells are
activated to become effector or memory T cells unless
there is immune intervention. To address how ATG
therapy affects antigen-stimulated T cells, we designed
and performed a series of experiments whereby NOD
mice were treated with ATG or isotype IgG, along with
simultaneous immunization by KLH protein in adjuvant
alum. All mice were sacrificed at day 22 post-treatment,
with spleen cells prepared and incubated with KLH, BSA
(unrelated antigen) and medium alone. We found that
KLH strongly stimulated spleen cells from both the ATG
and isotype IgG treated mice to comparable levels
(Figure 6A). Spleen cells from either group responded
poorly to BSA stimulation (Figure 6A). These findings
suggest that ATG therapy is unable to eliminate antigen-
primed T cells. We also found that spleen cells from
both groups responded to anti-CD3 antibody stimulation
similarly (Figure 6B). However, we also observed that
spleen cells from the ATG treated animals produced sig-
nificantly increased levels of IL-4, IL-5 and IL-10 along-
side of markedly reduced levels of IFN-γ in response to
stimulation of KLH (Figure 6C), in comparison to iso-
type IgG treated animals. These findings suggest that
despite the failure to eliminate antigen-specific T cells,
ATG therapy induces antigen-specific T cell responses
skewed to Th2 and Tr1, and largely limits the inflamma-
tory Th1 response.
ATG therapy fails to eliminate autoantigen-stimulated
T cells
From the results above, it appeared that ATG therapy is
unable to eliminate exogenous foreign antigen stimu-
lated T cells (Figure 6A). It is of interest to know how
ATG therapy affects self antigen-stimulated T cells. To
address this issue, we stimulated β cell antigen-specific
T cells in NOD mice at 6 weeks of age with an intraperi-
toneal injection of NIT1 (NOD mice insulinoma cell
line) lysates along with ATG or isotype IgG treatment,
as described previously. In these experiments, we did
not wait until 22 days post treatment to assess T cell
responses because of the concern that the exposure of
endogenous β antigens would continuously prime T
cells. Thus, at day 7 post-treatment, we sacrificed the
mice, with the spleen cells prepared and stimulated with
NIT1 lysates or unrelated antigen KLH. As expected, be-
cause of the transient significant depletion of T cells by
ATG therapy, in response to stimulation of the NIT1 cell
lysates, the proliferation of whole spleen cells from
CBA
D
P=0.0019
P=0.006
P=0.4839
P=0.015
G
FE
H
P=0.0051
P=0.0027 P=0.018
P=0.0096
Figure 4 Effect of ATG therapy on Foxp3+ Treg cells. NOD mice
were treated with ATG or isotype IgG twice with a 3-day interval. At
day 3 and 22, CD4+Foxp3+ regulatory T cells in spleen were
examined by flow cytometry and the summary of each group was
shown in Figure 4A and B, and 4C and D, respectively. At day 3,
CD4+Foxp3+ regulatory T cells in pancreatic and inguinal lymph
nodes were also examined and shown in Figure 4E and F, 4G and H,
respectively. Three mice were included in each group. The similar
results were obtained in additional two independent experiments.
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pared to isotype IgG treated animals (Figure 7A). How-
ever, compared to the unrelated antigen KLH, NIT1
lysates still significantly stimulated spleen cells from the
ATG treated animals (Figure 7A). To determine to what
degree the ATG therapy depletes β antigen-specific T
cells, we prepared spleen cells from the aforementioned
mice and then performed an adoptive transfer of CFSE-
labeled spleen cells to recipient NOD mice at 8 weeks of
age. Four days later, CD4+ T cell proliferation of CFSE-
labeled cells in inguinal and pancreatic lymph nodes was
examined by flow cytometry. As shown in Figure 7C, in
inguinal lymph nodes, the proliferation of CD4+ T cells
of injected CFSE-spleen cells from ATG treated animals
is slightly higher than that of CD4+ T cells from control
group, which may reflect the higher T cell homeostatic
proliferation potential post-ATG therapy [18]. More im-
portantly, we found the proliferation of CFSE-labeled
CD4+ T cells was much higher in pancreatic than in in-
guinal lymph nodes for both groups, which reflects β
cell-antigen specific T cell response. However, unexpect-
edly, in response to endogenous β cell antigens, the pro-
liferation of those injected CD4+ T cells from ATG
treated animals in pancreatic lymph node was signifi-
cantly higher than that of CD4+ T cells from isotype IgG
treated animals. These results further confirm that ATG
therapy fails to eliminate antigen-primed T cells. To
confirm this, we demonstrated that purified CD4+ T
cells from the spleen cells of both groups had compar-
able levels of proliferation in response to stimulation of
syngenic splenic DC plus NIT-1 lysates (Figure 7B).
Nevertheless, consistent with the results shown in
Figure 6C, the cytokine assay for the cultures shown in
Figure 7B demonstrated that ATG therapy suppressed β-
cell antigen-specific IFN-γ production but enhanced IL-
10 production by the CD4+ T cells (Figure 7D).
Discussion
In this study, we questioned how ATG therapy affected
naïve and memory T cells including Tregs with naïve or
memory phenotypes. Until now, it was unclear to what
extent ATG treatment affected naive and memory T cells
pools. Resolving this issue is of great significance in
managing ATG therapy in autoimmune diseases as well
BATG
Isotype IgG
A
Figure 5 Effect of ATG therapy on naive and memory Tregs. NOD mice were treated with ATG or isotype IgG twice with a 3-day interval. At
day 3 post treatment, the mice were sacrificed. The spleen cells were prepared and stained with CD4, CD25 CD62L and Foxp3 antibodies and
examined by flow cytometry. CD62L+Foxp3+ and CD62L-Foxp3+ Tregs were analyzed by gating the CD4+CD25+ cell population as shown in
Figure 5A. The summary of splenic CD62L+Tregs was shown in Figure 5B. ILN: inguinal lymph node; PLN: pancreatic lymph node. An additional
experiment was performed with similar results.
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reports [12], we found that ATG therapy markedly
depleted CD4+ and CD8+ T cells from the peripheral
blood, and largely spared B cells and granulocytes. By
day 3 post-treatment, T cell numbers reached their nadir.
By day 22, CD4+ T cells recovered to within normal
ranges, but CD8+ T cells remained lower than baseline.
It has been suggested that ATG therapy may have differ-
ential effects in depleting T cells in peripheral blood and
lymphoid organs dependent on dosing [19]. In this
study, we tested our treatment protocol with optimal ef-
ficacy in preventing or reversing type 1 diabetes (500 μg/
mouse × 2 doses 3 days apart) as described in our other
reports [11,12]. To determine the efficiency of our ATG
treatment protocol in depleting T cells from the lymph-
oid organs, we examined splenic CD4+ and CD8+ T
cells in both groups (ATG versus isotype IgG) at day 3
post-ATG therapy. We found that the depletion of both
CD4+ and CD8+ T cells was less efficient in spleen than
from peripheral blood. The similar results were obtained
in lymph nodes such as inguinal or pancreatic lymph
nodes (data not shown). Of interest, it appears that ATG
therapy preferentially depletes CD62L+ naive T cells
from the blood because the proportion of CD62L+CD4+
naive T cells was markedly reduced while CD44+CD62L-
CD4+ memory T cells as a fraction of total CD4+ T cells
were increased. We observed a similar significant trend in
the change of naive and memory T cells in spleen as well.
Whether this differential depleting effect of ATG exhibits
in local lymph nodes, especially in pancreatic lymph nodes
is of interest to be further addressed. It is unlikely that theincrease of memory T cells at day 3 post-ATG therapy is
due to the conversion from naïve T cells [20,21] because
ATG is still depleting T cells during this short period of
time post-ATG therapy, and homeostatic proliferation un-
likely leads to much in the way of T cell conversion.
The relative resistance of memory T cells to ATG-
induced T cell depletion would allow for survival of
memory T cells which potentially could lead to the
recurrence of allograft rejection or autoimmunity after
reconstitution of immune system post-ATG therapy.
Consistent with this, we demonstrated that the prolifera-
tion of spleen cells from mice receiving ATG and de
novo KLH immunization was as high as that of spleen
cells from isotype IgG treated animals in KLH recall
responses in vitro. We also found that β cell antigen-
primed T cells during ATG therapy could survive ATG
depletion as well. However, despite unaffected T cell
proliferation in response to antigen stimulation post-
ATG therapy, the T cell cytokine-producing profile in
ATG treated animals indicated that ATG therapy skewed
Th2 and possibly IL-10-producing Tr1, and reduced
IFN-γ-producing Th1 responses. We had previously
shown long-term reversal of diabetes in NOD mice
using ATG or ATG in combination with G-CSF [11,12]
and our current findings in this report provide a mech-
anistic basis for this in the skewing toward Th2 and/or
IL-10-producing Tr1 responses under the regimen of
ATG. In this study, although we focused our studies on
CD4+ T cells, it is also important to study phenotypic
and functional alterations of CD8+ T cells by the ATG
therapy, given the pathogenic role of CD8+ T cells in
A B
p=0.001 p=0.0002 p=0.004 p=0.0165
C
Figure 6 Effect of ATG therapy on antigen-stimulated T cell proliferation and cytokine production. NOD mice were treated with ATG or
isotype IgG along with intraperitoneal injections of KLH in Alum as described in Methods. All mice were sacrificed at day 22 post treatment. A,
spleen cells were incubated with KLH, BSA or media only; B, spleen cells were stimulated with anti-CD3 antibodies. All cultures were pulsed by
3H-thymidine (1 uCi/well) at day 4 for additional 16 hours. T cell proliferation was measured by scintillation counting. Triplicate wells were set up
for each incubation. Three animals were included in each group. C, The production of cytokines in the cultures with KLH shown in Figure 6A was
measured by Luminex assay. This experiment was repeated in additional two separate experiments with similar results.
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future studies. The memory T cell phenotypic character-
istics, as well as the functional alterations post-ATG
therapy, may allow the modulated antigen-primed T cells
to efficiently exert their regulatory functions in the per-
iphery through affecting their migrating and homing
capabilities, thereby preventing the recurrence of auto-
immunity in autoimmune diseases and allogeneic rejec-
tion in allogeneic transplantation. These findings also
implicate that ATG therapy plus antigen vaccination
could lead to synergistic effect on induction of antigen-
specific immune tolerance. Such information would be
of great significance for developing antigen-based immu-
notherapeutic strategy for autoimmune diseases such as
type 1 diabetes.
Prior to this effort, several mechanisms underlying
ATG immune modulation have been proposed. A com-
mon belief is that ATG therapy works by T cell depletion
through complement-mediated cell lysis and activation-
induced cell death. However, another view regarding
ATG therapy is that this agent exerts immunosuppres-
sive function beyond that of simple T cell depletion [7,9].ATG therapy may modulate immune response in vivo
through inhibiting chemokine-driven T cell chemotaxis
[22]. It may also influence the interaction between T
cells and endothelial cells through modulating expres-
sion of adhesion molecules [22]. Our recent study
showed that ATG therapy eliminated certain subset of
dendritric cells and induced tolerogenic dendritic cells
[10]. In addition, ATG therapy may facilitate tolerance
induction through ATG-mediated apoptosis of T cells;
because T cell apoptosis induced by anti-CD3 therapy
was recently demonstrated to be associated with CD3
antibody therapy-induced immune tolerance [23]. The
skewing of antigen-specific Th2 and IL-10-producing
regulatory T cells (i.e., Tr1) by ATG therapy demon-
strated in the current study suggests that the non-
depleted antigen-responding T cells, instead of causing
immune attack, may lead to antigen-specific restoration
of immune tolerance, which implies that ATG works as
immune modulator rather than immune suppressant.
As suggested previously, Foxp3+ Tregs may play a
major role in preventing autoimmune diabetes during
ATG therapy [11,12]. However, it is incompletely
Figure 7 Effect of ATG therapy on self antigen-specific T cells in vivo. A, Eight weeks old NOD mice were treated with ATG or isotype IgG
along with intraperitoneal injections of β cell antigens NIT1 lysates as described in the Method. A week post treatment, all mice were sacrificed
and spleen cells were prepared. Spleen cells (1 × 106/well) were incubated with NIT1 lysates, KLH (un-related antigen) or medium alone. Triplicate
wells were set up for each incubation. T cell proliferation was measured by 3H-thymidine incorporation assay as described in the Methods
section. Three mice were included in each group. Data shown represent the average of three mice+/−standard deviation (SD). B, Part of the
spleen cells were used to isolate CD4+ T cells and the isolated CD4+ T cells (2 × 105/well) were incubated with splenic dendritic cells (2 × 104/well)
purified from naive NOD mice in the presence of NIT1 lysates (20 μl/well). Triplicate wells were set up for each incubation. The proliferation of CD4+
T cells was measured by 3H-thymidine incorporation assay. Three mice were included in each group. Data shown represent the average of three mice
+/−SD. C, Part of the mixed spleen cells from the above 3 ATG or 3 isotype IgG treated animals were stained with CSFE. Then, the CFSE-labeled spleen
cells were intravenously injected into 8 weeks old naive NOD mice (3 mice per group). Four days later, the cells prepared from inguinal and pancreatic
lymph nodes were stained with CD4-PerCp. The percentages of the proliferating CFSE-labeled CD4+ T cells (dilution of CFSE) were examined by flow
cytometry. D, cytokines IFN-γ and IL-10 in the cultures shown in B were measured by luminex. Data shown represent average values of 3 mice+/−SD.
An additional experiment was performed with similar results.
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ently than conventional T cells and how ATG affects the
distribution of Tregs in different lymphoid tissues. It is
also unclear whether ATG therapy affects naïve and
memory Tregs differently. In the present study, we
demonstrated that ATG therapy was less efficient in de-
pleting CD4+Foxp3+Tregs and as a result, the propor-
tion of CD4+Foxp3+ Tregs in CD4+ T cells was
significantly increased in ATG treated animals comparedto controls. This increase is even more dramatic in
lymph nodes with greater than a doubling in the fre-
quency of Tregs within total CD4+ T cells in ATG trea-
ted as compared to isotype IgG treated animals. In some
animals, the percentage of Foxp3+ Tregs reaches 30% of
total lymph node CD4+ T cells. Unlike equivalent abso-
lute numbers of splenic Tregs in both groups, the abso-
lute number of Tregs in lymph nodes was significantly
higher in ATG than in Isotype IgG treated group at 3
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recruiting to the lymph nodes besides resistance to ATG
depletion. The increase of Tregs in lymph nodes may be
of great immunological significance for ATG to control
local antigen-specific immune responses in the settings
of autoimmunity such as type 1 diabetes, as well as in
allogeneic transplantation. This increase of Tregs 3 days
post-ATG therapy is unlikely due to the preferential pro-
liferation of Tregs in the ATG-therapy induced lympho-
penic animals [24] because the proliferation is limited in
this short period of time especially still under active T
cell depletion. Of interest, by day 22 post-ATG treat-
ment when CD4+ T cells return to the normal levels,
Tregs remained proportionately higher in the ATG
group than in control group, which may be attributable
to a faster proliferation of Tregs than conventional T
cells [24] because Tregs possess superior capability to
utilize IL-2 to conventional T cells [25]. This may also
explain why a short-term ATG therapy offers a long-
term protection in type 1 diabetes [11,12] and in allo-
geneic transplantation [2,26]. Intriguingly, Tregs with
memory T cell phenotype were preferentially preserved
in ATG therapy, which suggests that the preserved
memory Tregs specific to certain antigens would be
more potent in suppressing effector T cells reactive to
the same antigens. As suggested recently [27], the mem-
ory Tregs may home to areas with active immunological
reaction to quickly exert their regulatory function prefer-
entially to naïve Tregs. This also explains the findings in
our recent report that the post-therapy Tregs gain
heightened immunosuppressive capacity [11]. There is
evidence that the progression of autoimmunity in NOD
mice leads to memory-like CD8+ Tregs which can be
expanded in vivo by stimulation of nanoparticles coated
with MHC-carried autoantigenic peptides. Of note, in-
jection of these nanoparticles not only prevented T1D
but also reversed overt diabetes in NOD mice [28].
Thus, the quantitative and qualitative changes of Tregs
post ATG therapy may play an important role in sup-
pressing antigen-specific effector T cells. Although Tregs
are generally thought to suppress T cell responses in an
antigen non-specific manner, emerging evidence shows
that antigen-specific Tregs are more potent in suppres-
sing antigen-specific T cell responses [29-31]. Lu, et al.
reported recently that ATG therapy indeed induced self-
antigen-specific Tregs in vivo that could provide long-
term T1D protection in NOD mice [32]. Whether the
increased memory Tregs post ATG therapy plus antigen
challenge in our experimental settings contain more
antigen-specific Tregs needs to be further explored.
Conclusions
ATG therapy preferentially depletes naive T cells, largely
spares Tregs and alters T cell cytokine-producingprofiles. Thus, ATG therapy may modulate antigen-
specific immune responses through inducing memory-
like regulatory T cells as well as other protective T cells
such as Th2 and IL-10-producing Tr1 cells.
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